Study identifier:D2840C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I, Open-Label Study to Assess the Safety, Tolerability and Pharmacokinetics of Ascending Doses of MEDI-575 in Patients with Advanced Solid Malignancies
Advanced solid malignancies
Phase 1
No
MEDI-575
All
23
Interventional
20 Years - 150 Years
Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Mar 2014 by MedImmune, LLC
MedImmune, LLC
MedImmune
The purpose of this study is to evaluate the safety and tolerability of MEDI-575 in Japanese patients with advanced solid tumors (dose escalation part) and hepatocellular carcinoma (expansion part).
Location
Location
Sunto-gun, Japan
Location
Nagoya, Aichi, Japan
Location
Kashiwa, Chiba, Japan
Location
Chuo-ku, Tokyo, Japan
Location
Matsuyama, Ehime, Japan
Location
Chuo-ku, Japan
Location
Kashiwa-shi, Japan
Location
Nagoya-shi, Japan
Arms | Assigned Interventions |
---|---|
Experimental: 1 | Drug: MEDI-575 MEDI-575 will be administered weekly or every 3 weeks as IV infusion as part of a 21-day treatment cycle. One or two doses will be selected for expansion part |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.